NASDAQ:PTIX Atrinsic (PTIX) Stock Price, News & Analysis $3.55 -0.35 (-8.97%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$3.72 +0.17 (+4.79%) As of 08/28/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Atrinsic Stock (NASDAQ:PTIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Atrinsic alerts:Sign Up Key Stats Today's Range$3.52▼$3.8950-Day Range$2.28▼$4.5152-Week Range$2.25▼$15.54Volume250,697 shsAverage Volume8.33 million shsMarket Capitalization$2.09 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York. Read More Atrinsic Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScorePTIX MarketRank™: Atrinsic scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Atrinsic. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Atrinsic is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atrinsic is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtrinsic has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Atrinsic's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.46% of the float of Atrinsic has been sold short.Short Interest Ratio / Days to CoverAtrinsic has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Atrinsic has recently increased by 10.10%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtrinsic does not currently pay a dividend.Dividend GrowthAtrinsic does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.46% of the float of Atrinsic has been sold short.Short Interest Ratio / Days to CoverAtrinsic has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Atrinsic has recently increased by 10.10%, indicating that investor sentiment is decreasing significantly. News and Social Media3.1 / 5News SentimentN/A News SentimentAtrinsic has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Atrinsic this week, compared to 0 articles on an average week.Search Interest18 people have searched for PTIX on MarketBeat in the last 30 days. This is an increase of 1,700% compared to the previous 30 days.MarketBeat Follows2 people have added Atrinsic to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Atrinsic insiders have not sold or bought any company stock.Percentage Held by Insiders35.00% of the stock of Atrinsic is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.97% of the stock of Atrinsic is held by institutions.Read more about Atrinsic's insider trading history. Receive PTIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atrinsic and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTIX Stock News HeadlinesProtagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug CandidatesJuly 30, 2025 | globenewswire.comProtagenic Therapeutics, Inc. (PTIX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia. | The Oxford Club (Ad)Protagenic & Phytanix Merge in All-Stock Move, Sparking Retail FrenzyMay 29, 2025 | msn.comProtagenic Therapeutics swaps warrants for sharesMay 21, 2025 | uk.investing.comProtagenic Therapeutics Shares Double After Buyout Offer From Phytanix BioMay 20, 2025 | marketwatch.comProtagenic Therapeutics stock soars on merger to create Neuroactive Biopharmaceutical companyMay 20, 2025 | in.investing.comProtagenic Therapeutics Merges With Phytanix Bio In All-Stock Deal: Retail Turns Extremely BullishMay 20, 2025 | msn.comSee More Headlines PTIX Stock Analysis - Frequently Asked Questions How have PTIX shares performed this year? Atrinsic's stock was trading at $6.86 on January 1st, 2025. Since then, PTIX shares have decreased by 48.3% and is now trading at $3.55. How were Atrinsic's earnings last quarter? Atrinsic Inc. (NASDAQ:PTIX) issued its earnings results on Tuesday, May, 13th. The company reported ($2.75) EPS for the quarter. When did Atrinsic's stock split? Atrinsic shares reverse split before market open on Monday, May 5th 2025.A 1-14 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, May 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Atrinsic? Shares of PTIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atrinsic own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atrinsic investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), NVIDIA (NVDA), Cytokinetics (CYTK), Heatwurx (PCSA), Acasti Pharma (ACST) and Akero Therapeutics (AKRO). Company Calendar Last Earnings5/13/2025Today8/29/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTIX CIK1022899 Webwww.protagenic.com Phone212-994-8200Fax603-761-6223Employees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)($13.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.53 million Net MarginsN/A Pretax MarginN/A Return on Equity-860.52% Return on Assets-354.19% Debt Debt-to-Equity RatioN/A Current Ratio0.86 Quick Ratio0.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.96 per share Price / Book1.81Miscellaneous Outstanding Shares589,000Free Float383,000Market Cap$2.09 million OptionableNot Optionable Beta0.34 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:PTIX) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atrinsic Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atrinsic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.